DIAMEDICA THERAPEUTICS INC COMMON SHARES (DMCAF)
DMCAF moved a median of -0.63% 30 minutes after news, and +1.00% by the close. How DMCAF actually reacts to news — the realized, point-in-time move the market made, measured across 1 labeled events over its full measured history with zero look-ahead.
DMCAF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.90% | 0% | 1 |
| 30-min | -0.63% | 0% | 1 |
| 60-min | -0.57% | 0% | 1 |
| to close | +1.00% | 100% | 1 |
Small sample: only 1 measured events — treat these medians as indicative, not stable.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when DMCAF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to DMCAF's baseline. Nothing else.
Recent DMCAF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 for Fetal Growth Restriction Featuring Early Phase 2 FGR Results | Press release | Business Wire | +1.45% | +0.00% | |
| DiaMedica Therapeutics to Participate in Upcoming September Investor Conferences | Press release | Business Wire | +0.98% | +2.27% | |
| Form S-8 DiaMedica Therapeutics | SEC filing · Form S-8 | SEC EDGAR | +0.15% | +3.00% | |
| DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026 | Press release | Business Wire | +1.14% | +0.98% | |
| DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | +1.65% | -3.84% | |
| DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction | Press release | Business Wire | +2.25% | +8.65% | |
| DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program | Press release | Business Wire | -0.52% | -1.56% | |
| DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026 | Press release | Business Wire | -0.17% | +1.65% | |
| Form 8-K DiaMedica Therapeutics For: May 20 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +2.43% | |
| DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial | Press release | Business Wire | +0.18% | +3.44% | |
| DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference | Press release | Business Wire | +0.56% | +0.81% | |
| DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights | Press release | Business Wire | -1.71% | +1.40% | |
| Form 10-Q DiaMedica Therapeutics For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.71% | +1.40% | |
| Form 8-K DiaMedica Therapeutics For: May 06 | SEC filing · Form 8-K | SEC EDGAR | -1.71% | +1.40% | |
| DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026 | Press release | Business Wire | +3.69% | +1.51% | |
| RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms | Press release | ACCESS Newswire | +0.31% | +1.08% | |
| Form ARS DiaMedica Therapeutics For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | +1.82% | +3.35% | |
| Form DEF 14A DiaMedica Therapeutics For: May 20 | SEC filing · Form DEF | SEC EDGAR | +1.82% | +3.35% | |
| Form DEFA14A DiaMedica Therapeutics | SEC filing · Form DEFA14A | SEC EDGAR | +1.82% | +3.35% | |
| Form 8-K DiaMedica Therapeutics For: Mar 30 | SEC filing · Form 8-K | SEC EDGAR | -3.36% | -5.18% | |
| DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights | Press release | Business Wire | -3.36% | -5.18% | |
| Form 10-K DiaMedica Therapeutics For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.36% | -5.18% | |
| DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026 | Press release | Business Wire | +1.16% | +5.35% | |
| DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia | Press release | Business Wire | -1.18% | -0.26% | |
| DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences | Press release | Business Wire | +0.00% | +2.03% | |
| DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -3.23% | -0.14% | |
| Form 8-K DiaMedica Therapeutics For: Jan 05 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +6.75% | |
| DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA | Press release | Business Wire | -1.18% | -1.89% | |
| Form 8-K DiaMedica Therapeutics For: Dec 18 | SEC filing · Form 8-K | SEC EDGAR | -1.18% | -1.89% | |
| DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights | Press release | Business Wire | +0.95% | — | |
| Form 10-Q DiaMedica Therapeutics For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +0.95% | — | |
| Form 8-K DiaMedica Therapeutics For: Nov 12 | SEC filing · Form 8-K | SEC EDGAR | +0.95% | — | |
| DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London | Press release | Business Wire | -1.49% | +0.33% | |
| DiaMedica Therapeutics to Report Third Quarter 2025 Financial Results and Provide a Business Update November 13, 2025 | Press release | Business Wire | -1.21% | -4.21% | |
| DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) | Press release | Business Wire | -0.43% | -0.43% | |
| DiaMedica Therapeutics to Participate in Upcoming Investor Conferences | Press release | Business Wire | +2.54% | +11.23% | |
| DiaMedica Therapeutics to Participate in Cantor Global Healthcare Conference | Press release | Business Wire | -1.75% | -6.83% | |
| Form EFFECT DiaMedica Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | +0.66% | -0.33% | |
| DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights | Press release | Business Wire | +2.86% | +22.45% | |
| Form 10-Q DiaMedica Therapeutics For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.86% | +22.45% | |
| Form 8-K DiaMedica Therapeutics For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | +2.86% | +22.45% | |
| Form S-3 DiaMedica Therapeutics | SEC filing · Form S-3 | SEC EDGAR | +2.86% | +22.45% | |
| Form EFFECT DiaMedica Therapeutics | SEC filing · Form EFFECT | SEC EDGAR | -3.21% | -1.93% | |
| DiaMedica Therapeutics Appoints Julie Krop, MD, as Chief Medical Officer | Press release | Business Wire | -0.64% | +0.00% | |
| Form 8-K DiaMedica Therapeutics For: Aug 04 | SEC filing · Form 8-K | SEC EDGAR | -0.64% | +0.00% | |
| DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025 | Press release | Business Wire | -0.64% | +0.00% | |
| Form S-3 DiaMedica Therapeutics | SEC filing · Form S-3 | SEC EDGAR | -2.04% | -0.96% | |
| Form D DiaMedica Therapeutics | SEC filing · Form D | SEC EDGAR | -0.10% | +2.85% | |
| DiaMedica Therapeutics Announces Closing of $30.1 Million Private Placement | Press release | Business Wire | -0.85% | -4.13% | |
| DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline | Press release | Business Wire | +10.71% | +8.10% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the DMCAF section they belong to.
Where else DMCAF is measured.
DMCAF earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| SANTEN PHARM CO UNSP/ADR (SNPHY) | 2 | 0.00% | 0% |
| TODOS MED LTD ORD (TOMDF) | 2 | +8.33% | 50% |
| EUROFINS SCIENTIFIC SA (ERFSF) | 1 | +0.07% | 100% |
| IMRIS INC (IMRSQ) | 1 | 0.00% | 0% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is DIAMEDICA THERAPEUTICS INC COMMON SHARES's median reaction calculated?
Every labeled DMCAF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 1 events is what this page reports. On a sample this small (1 events), treat these medians as indicative, not stable. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does DMCAF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.